InMed Pharmaceuticals Inc. 8-K

What Happened
InMed Pharmaceuticals Inc. announced amendments to previously issued preferred investment options with Sabby Volatility Warrant Master Fund, Ltd. and affiliates of H.C. Wainwright & Co., LLC. On April 21, 2026, InMed amended the Sabby options to reduce the exercise price from $2.436 to $0.80 for up to 2,151,478 common shares. On April 24, 2026, InMed executed similar amending agreements with the Wainwright parties, changing the three earlier exercise prices (previously $82.50, $20.75 and $3.2013, post‑consolidation) to $0.80 for a combined total of up to 153,236 common shares (post‑consolidation). The company issued a press release on April 27, 2026 announcing these amendments.

Key Details

• Sabby amendment: reduces exercise price from $2.436 to $0.80 for up to 2,151,478 common shares (agreements dated Oct 26, 2023 and June 26, 2025; amendment dated Apr 21, 2026).
• Wainwright amendments: reduce three exercise prices to $0.80 for affiliates of H.C. Wainwright (original options dated Nov 21, 2022; Oct 26, 2023; June 26, 2025; amendments dated Apr 24, 2026) covering up to 153,236 common shares (post‑consolidation).
• The original options were private placements under Section 4(a)(2)/Regulation D. The company filed the amending agreements as exhibits to the 8-K and issued a press release (Exhibit 99.1).

Why It Matters
Lowering the exercise price to $0.80 makes it easier for these option holders to convert into common shares, which could increase potential dilution if the options are exercised. Investors should review the filed amending agreements and the press release for details and monitor any future share issuances or financing-related disclosures that could affect the company’s capitalization.